MarketCap
Facebook
X
TelegramQuarterly report 2023-Q1
added 05-10-2023
Syneos Health Operating Income 2011-2026 | SYNH
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income Syneos Health
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 389 M | 293 M | 238 M | 160 M | -28.9 M | 155 M | 152 M | 63.6 M | 31.5 M | -37.5 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 389 M | -37.5 M | 142 M |
Quarterly Operating Income Syneos Health
| 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -39.5 M | - | - | - | 73.9 M | - | 113 M | 83.7 M | 61 M | - | 98.8 M | 35 M | 49 M | 83.4 M | 69.4 M | 58.1 M | 26.8 M | 79.5 M | 39.8 M | 30.7 M | 10.2 M | 15 M | -88.9 M | 10.2 M | 34.8 M | 43.8 M | 39.4 M | 39.7 M | 32.5 M | 39.7 M | 44.3 M | 35.9 M | 32.4 M | 18.5 M | 22.7 M | 7.87 M | 14.6 M | 11.3 M | 15 M | 4.79 M | 370 K | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 113 M | -88.9 M | 34.6 M |
Operating Income of other stocks in the Diagnostics research industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
-46 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Aspira Women's Health
AWH
|
-7.91 M | - | -6.19 % | $ 10.5 M |  USA |
 |
Agilent Technologies
A
|
1.35 B | $ 115.39 | -1.31 % | $ 35.1 B | USA |
 |
Biocept
BIOC
|
-32 M | - | -13.05 % | $ 7.29 M | USA |
 |
BioNano Genomics
BNGO
|
-33.3 M | $ 1.16 | -1.69 % | $ 6.32 M | USA |
 |
Chembio Diagnostics
CEMI
|
-23.6 M | - | 0.22 % | $ 16.8 M | USA |
 |
DermTech
DMTK
|
-104 M | - | -11.32 % | $ 2.94 M | USA |
 |
CareDx, Inc
CDNA
|
-30.8 M | $ 16.69 | -6.86 % | $ 889 M | USA |
|
Akumin
AKU
|
-28.1 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Enzo Biochem
ENZ
|
-12.4 M | - | -8.98 % | $ 14.8 K | USA |
 |
Burning Rock Biotech Limited
BNR
|
-797 M | $ 16.25 | 0.06 % | $ 175 M |  China |
 |
Exact Sciences Corporation
EXAS
|
-206 M | - | - | $ 19.8 B | USA |
 |
Co-Diagnostics
CODX
|
-50.2 M | $ 4.4 | 101.83 % | $ 5.85 M | USA |
 |
Accelerate Diagnostics
AXDX
|
-14 M | - | -61.36 % | $ 2.46 M | USA |
 |
Castle Biosciences
CSTL
|
8.67 M | $ 23.43 | -6.99 % | $ 651 M | USA |
 |
Global Cord Blood Corporation
CO
|
609 M | - | - | $ 399 M | China |
 |
Genetron Holdings Limited
GTH
|
-518 M | - | 0.12 % | $ 80.1 M | China |
 |
Charles River Laboratories International
CRL
|
25.2 M | $ 175.55 | 0.27 % | $ 8.7 B | USA |
 |
Danaher Corporation
DHR
|
4.69 B | $ 192.99 | -1.63 % | $ 138 B | USA |
 |
Heska Corporation
HSKA
|
-20.3 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
-20.8 M | - | -20.0 % | $ 1.06 M | USA |
 |
Interpace Biosciences
IDXG
|
4.08 M | $ 2.3 | 16.02 % | $ 10.2 M | USA |
 |
Illumina
ILMN
|
-833 M | $ 123.67 | -3.38 % | $ 19.7 B | USA |
 |
Fulgent Genetics
FLGT
|
-73.9 M | $ 15.02 | -5.12 % | $ 454 M | USA |
 |
Koninklijke Philips N.V.
PHG
|
553 M | $ 28.13 | 0.29 % | $ 20 B |  Niderland |
 |
Guardant Health
GH
|
-437 M | $ 87.17 | -6.11 % | $ 10.9 B | USA |
 |
QIAGEN N.V.
QGEN
|
466 M | - | - | $ 10.6 B | Niderland |
 |
Anixa Biosciences
ANIX
|
-11.7 M | $ 2.74 | 0.37 % | $ 88.9 K | USA |
 |
Biomerica
BMRA
|
-5.14 M | $ 2.2 | 2.33 % | $ 5.05 M | USA |
 |
ICON Public Limited Company
ICLR
|
1.1 B | $ 106.7 | 0.15 % | $ 8.8 B |  Irlanda |
 |
Check-Cap Ltd.
CHEK
|
-25.9 M | - | - | $ 9.42 M |  Israel |
 |
Laboratory Corporation of America Holdings
LH
|
1.38 B | $ 273.26 | -0.53 % | $ 22.7 B | USA |
 |
Celcuity
CELC
|
-172 M | $ 124.64 | 6.58 % | $ 5.83 B | USA |
 |
Medpace Holdings
MEDP
|
535 M | $ 501.5 | -3.68 % | $ 14.5 B | USA |
 |
Lantheus Holdings
LNTH
|
311 M | $ 81.43 | 1.75 % | $ 5.5 B | USA |
 |
Motus GI Holdings
MOTS
|
-11.9 M | - | -34.28 % | $ 263 K | Israel |
 |
Myriad Genetics
MYGN
|
-387 M | $ 4.44 | -6.92 % | $ 411 M | USA |
 |
Quest Diagnostics Incorporated
DGX
|
1.56 B | $ 197.82 | -0.5 % | $ 22 B | USA |
 |
NeoGenomics
NEO
|
-116 M | $ 7.94 | -3.38 % | $ 1.02 B | USA |
 |
Neogen Corporation
NEOG
|
-1.06 B | $ 10.04 | -2.95 % | $ 2.18 B | USA |
 |
ENDRA Life Sciences
NDRA
|
-5.76 M | $ 5.31 | 2.71 % | $ 4.18 M | USA |
 |
National Research Corporation
NRC
|
22.6 M | $ 17.05 | -1.22 % | $ 382 M | USA |
 |
Natera
NTRA
|
-541 M | $ 203.0 | -3.71 % | $ 20 B | USA |
 |
Invitae Corporation
NVTA
|
-94.9 M | - | - | $ 21.2 M | USA |
 |
Organovo Holdings
ONVO
|
-12.6 M | - | -2.3 % | $ 19.4 M | USA |
 |
OpGen
OPGN
|
325 K | - | -16.95 % | $ 1.54 M | USA |